In the retrospective part of the study, Tissue Microarrays (TMA) will be prepared from surgical samples of breast tissue from a series of patients with TNBC type breast cancer.
In the prospective part of the study will be evaluated the expression of some selenoproteins by ELISA in plasma samples obtained from up to 100 healthy subjects and about 300 (\~100 per year) patients with basally metastatic TNBC breast cancer (150) and metastatic (150) before any treatment.
Age
18–any
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
TNBC breast cancer patients, before any drug treatment
healthy women aged 25-60
You may not be if
donors suffering from diabetes, hypertension, active infectious states, HIV infection, Hepatitis B or C, chronic inflammatory diseases, current or previous neoplasms, heart disease or drug treatment.
Clareo Health | Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.
